Consumer-focused guidance emphasizes CKD testing, individualized care, evidence review, and caution around "reversal" and "detox" claims made by online kidney-health programs.
AURORA, Colorado — September 4, 2026 — The Chronic Kidney Disease Solution today announced new consumer guidance aimed at helping individuals evaluate chronic kidney disease (CKD) information available online. The program’s accompanying materials emphasize the importance of medical testing, CKD staging, and evidence-based care, and state explicitly that the program is not a substitute for physicians, nephrologists, laboratory testing or prescribed treatment.
“We built this guidance because we kept seeing the same pattern: someone gets a concerning lab result, searches online, and finds a dozen programs promising to reverse their kidney disease with no testing, no oversight and no way to check if it actually worked for anyone else,” said Shelly Manning of The Chronic Kidney Disease Solution. “Our position is that a consumer should be able to ask basic questions — was this program itself studied, not just one ingredient in it, and who’s actually making the recommendations — before they spend money on it.”
The program’s materials address how consumers can evaluate claims made by online kidney-health programs generally — including questions about the evidence supporting a specific protocol, the qualifications of people providing advice, ingredient and dosing disclosures, payment terms, and whether published research actually evaluated the program in question rather than a single ingredient in isolation. The CKD Digital Access available on their official website.
Distinguishing Ingredient Research From Program-Level Evidence
The materials distinguish between research involving an individual food, vitamin, herb or lifestyle practice and clinical research involving a complete commercial protocol. They recommend that consumers look for studies of the exact program under consideration, including details about study participants, sample size, comparison groups, study duration and clinically meaningful outcomes — rather than accepting that evidence for one ingredient demonstrates a program built around it is effective.
Potential clinical measures discussed include estimated glomerular filtration rate (eGFR), urine albumin, blood pressure, blood glucose and the rate of kidney-function decline over time. The materials caution that an isolated change in a single measure such as creatinine does not by itself demonstrate that damaged kidney tissue has been restored, and that meaningful evaluation requires tracking multiple measures over time under professional supervision.
That distinction is consistent with current clinical guidance. KDIGO’s 2024 Clinical Practice Guideline for the Evaluation and Management of CKD — the organization’s first full update since 2012 — addresses evaluation, classification, risk assessment, medication management and individualized treatment, rather than treating CKD as a condition that can be assessed from symptoms or a single lab value alone.
CKD Testing and Staging Remain Central to Evaluation
The materials emphasize that CKD can exist without obvious symptoms and that diagnosis requires appropriate medical evaluation. They discuss eGFR and the urine albumin-to-creatinine ratio (UACR) as the primary measures used to assess kidney function and kidney damage, and note that CKD management depends on a combination of factors: the underlying cause, eGFR, UACR, blood pressure, diabetes status, age, cardiovascular conditions, current medications and the rate at which kidney function is changing.
The scale of the condition is significant. The Centers for Disease Control and Prevention estimates that more than 1 in 7 U.S. adults — about 35.5 million people — have CKD, and that a large share of people with early-stage disease are unaware they have it. According to CDC data, as many as 9 in 10 adults with CKD do not know they have the condition, and roughly 1 in 3 adults with severe CKD are similarly unaware. The materials position these statistics as part of the rationale for the program’s emphasis on testing rather than symptom-based self-assessment, on the reasoning that a program built around self-reported symptoms cannot substitute for the lab measures used in clinical staging.
Evidence-Based CKD Management
Rather than presenting a single nutritional or lifestyle intervention as appropriate for everyone, the program’s materials describe several established areas of CKD management: blood-pressure control, diabetes management, individualized nutrition guidance and periodic medication review. For people with appropriate clinical indications, evidence-based CKD care can include medication classes such as ACE inhibitors, ARBs and SGLT2 inhibitors, with treatment decisions depending on an individual’s specific clinical circumstances. KDIGO’s current guideline provides recommendations for these therapies and emphasizes ongoing monitoring alongside individualized care rather than a fixed protocol applied uniformly.
The materials caution against changing prescription medications on the basis of an online program’s recommendations, and recommend professional supervision for any treatment decision.
Caution Around Supplements and “Kidney Detox” Claims
A recurring focus of the program’s consumer materials is the risk associated with supplements and highly restrictive diets in people with reduced kidney function. The materials note that reduced kidney function can change how the body handles medications and supplements, and recommend that consumers disclose all supplements, herbal products, vitamins, minerals and over-the-counter medicines to a healthcare professional before use. The materials specifically warn against claims involving guaranteed results, undisclosed “secret” ingredients, dialysis avoidance, or universal CKD cures.
This caution reflects existing regulatory guidance. The FDA states that dietary supplements are not approved by the agency for safety or effectiveness before they reach the market, and that supplements cannot lawfully be marketed as products intended to diagnose, treat, cure or prevent disease. The FTC similarly states that objective health claims made in advertising require appropriate substantiation, and that health-related claims generally require competent and reliable scientific evidence before they can be made.
How Consumers Can Verify Claims Before Purchasing
The program’s materials recommend that consumers evaluate several factors before purchasing any kidney-health product or program: the identity and background of the seller, the specific contents of the program, total pricing, refund terms, and whether the purchase involves a recurring charge. They also encourage consumers to verify the professional credentials of anyone promoting a program and to examine whether that person has an undisclosed financial interest in supplements, coaching services, laboratory testing or paid memberships connected to their recommendations.
The materials recommend that consumers begin with an appropriate medical evaluation and bring medication and supplement lists, blood-pressure readings and relevant lab records to a healthcare appointment rather than beginning any new protocol independently. They note that referral to a nephrologist may be appropriate in circumstances such as advanced CKD, substantial albuminuria, rapid kidney-function decline, or a cause of kidney disease that has not been identified.
Frequently Asked Questions
Is The Chronic Kidney Disease Solution a substitute for medical treatment? No. The program’s materials state explicitly that it is not a substitute for physicians, nephrologists, laboratory testing or prescribed treatment, and recommend professional medical evaluation for CKD diagnosis and management.
What should I ask before trusting a kidney-health program’s claims? The materials recommend checking whether cited research evaluated the specific program (not just an individual ingredient), reviewing the credentials of who is providing the advice, and confirming pricing, refund terms and any recurring charges before purchasing.
Why do the materials focus on eGFR and UACR rather than symptoms? Because CKD frequently has no obvious symptoms in its earlier stages, the materials state that appropriate testing — rather than how a person feels — is necessary to assess kidney function and detect damage.
Does the program recommend stopping or changing prescription medication? No. The materials caution against changing prescription medications based on an online program and recommend that any medication change be made under a healthcare provider’s supervision.
How is the program distributed? The program is offered as a digital publication with stated lifetime access, distributed through ClickBank and available via the company’s retail site.
What is the difference between CKD staging and a general wellness claim? CKD staging relies on standardized clinical measures — primarily eGFR and UACR — interpreted by a healthcare provider against established thresholds. A general wellness or “detox” claim typically does not reference these measures and cannot establish whether kidney function has actually changed.
Why do the materials caution against “kidney detox” language specifically? Because reduced kidney function changes how the body processes substances, including over-the-counter supplements, the materials treat unverified detox claims as a potential safety concern rather than only a marketing exaggeration, and recommend disclosing all supplement use to a healthcare provider.
About The Chronic Kidney Disease Solution
The Chronic Kidney Disease Solution is presented as a commercial health program distributed through a direct-to-consumer platform and authorized retail partners. [Note to editor: describe the program’s actual content here — e.g., its format, author/creator background, and what specific guidance or protocol it provides — once confirmed with the client. Do not state authorship or professional credentials (e.g., “authored by experts in nephrology and nutrition”) unless the client has confirmed that specific claim; it is not established anywhere in the supplied materials.] Its consumer materials focus on evaluating kidney-health claims, understanding CKD testing and staging, reviewing evidence, and recognizing situations where professional medical care is appropriate. The program does not present itself as a replacement for medical diagnosis or treatment, and its materials state that people with diagnosed CKD should weigh their individual kidney function, medications, laboratory results and other health factors when evaluating any dietary, supplement or lifestyle protocol. The program offers lifetime digital access and a 60-day satisfaction guarantee, and is distributed via ClickBank.
Disclaimer: This release describes consumer educational materials and general information about chronic kidney disease. It is not medical advice. Individuals with CKD or symptoms of kidney disease should consult a licensed healthcare professional for diagnosis and treatment.This press release contains links to a retail partner website through which the distributor may receive compensation if a purchase is made following a referral, disclosed in accordance with the Federal Trade Commission’s guidelines on endorsements and testimonials (16 CFR Part 255). This relationship does not influence the factual content of this release.
Media Contact
Shelly Manning, Media Relations, The Chronic Kidney Disease Solution
Email: support@blueheronhealthnews.com
Phone: +1 (203) 872-9584
Address: 1444 S. Entertainment Ave., Suite 410 Boise, ID 83709
Website: blueheronhealthnews.com
For more press release distribution and guest post services, visit TS Newswire.
